Top

Clinical Reviews in Allergy & Immunology

Published in:

22-07-2021 | Primary Immunodeficiency

Newborn Screening in the Diagnosis of Primary Immunodeficiency

Author: Lisa J. Kobrynski

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2022

Abstract

Newborn screening for severe combined immune deficiency (SCID) is the first inborn error of immunity (IEI) to be detected through population screening. It also represents the first newborn screening test to utilize molecular testing on DNA from newborn dried blood spots. Newborn screening for SCID has provided opportunities to measure the population prevalence of this disorder and evaluate the effect of early interventions on the overall outcomes in affected infants. The success of SCID newborn screening has increased interest in developing and implementing molecular testing for other clinically significant inborn errors of immunity. This methodology has been adapted to screen for another monogenic inborn defect, spinal muscle atrophy. Advances in the clinical care and new therapeutics for many inborn errors of immunity support the need for early diagnosis and prompt institution of therapies to reduce morbidity and mortality. Early diagnosis may also improve the quality of life for affected patients. This article provides an overview of newborn screening for SCID, recommended steps for follow-up testing and early intervention as well as long-term follow-up. Numerous challenges remain, including the development of clinical consensus regarding confirmatory and diagnostic testing, early interventions, and best practices for immune reconstitution in affected infants.

Myers LA, Patel DD, Puck JM, Buckley RH (2002) Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99:872–878. https://doi.org/10.1182/blood.v99.3.872

Pai SY, Logan BR, Griffith LM et al (2014) Transplantation outcomes for severe combined immunodeficiency, 2000–2009. New Engl J Med 371:434–46. https://doi.org/10.1056/NEJMoa1401177

Wilson JM, Jungner YG (1968) Principles and practice of screening for disease. WHO Chronicle, Geneva: World Health Organisation 22:473

Chan K, Puck JM (2005) Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 115(2):391–398. https://doi.org/10.1016/j.jaci.2004.10.012

Baker MW, Grossman WJ, Laessig RH et al (2009) Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol 124(3):522–527. https://doi.org/10.1016/j.jaci.2009.04.007

Kwan A, Abraham RS, Currier R et al (2014) Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 312(7):729–738. https://doi.org/10.1001/jama.2014.9132

Newborn screening for severe combined immunodeficiency (2009) a summary of the evidence and Advisory Committee decision Report date 29 April, 2009. https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/scid-27-june-2018.pdf. Accessed 01 March 2021

Puck JM (2019) Newborn screening for severe combined immunodeficiencies and T-cell lymphopenia. Immunol Reviews 287:241–252. https://doi.org/10.1111/imr.12729

Shearer WT, Dunn E, Notarangelo LD et al (2014) Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 133(4):1092–1098. https://doi.org/10.1016/j.jaci.2013.09.044

10.

Buckley RH (2011) Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: long term outcomes. Immunol Res 49:25–43. https://doi.org/10.1007/s12026-010-8191-9

11.

Heimall J, Logan BR, Cowan MJ, Notarangelo LD, Griffin L, Puck JM et al (2017) Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood 21:2718–2727. https://doi.org/10.1182/blood-2017-05-781849

12.

Hershfield MS, Buckley RH, Melton GML, AL, Schiff R, Hatem C et al (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 316:589–596CrossRef

13.

Chan B, Wara D, Bastian J et al (2005) Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol 117(2):133–143. https://doi.org/10.1016/j.clim.2005.07.006 Epub 2005 Aug 22

14.

Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB et al (2019) Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol 143:852–863. https://doi.org/10.1016/j.jaci.2018.08.024 Epub 2018 Sep 5

15.

Aiuti A, Cattaneo F, Galimberti S et al (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360(5):447–58. https://doi.org/10.1056/NEJMoa0805817

16.

Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease Science 288:669–672. https://doi.org/10.1126/science.288.5466.669

17.

Hacein-Bey-Abina S, Le Deist F, Carlier F et al (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy N Engl J Med 346:1185–1193. https://doi.org/10.1056/NEJMoa012616

18.

Mamcarz E, Zhou S, Lockey T et al (2019) Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1. N Engl J Med 380(16):1525–1534. https://doi.org/10.1056/NEJMoa1815408

19.

Punwani D, Kawahara M, Yu J, Sanford U, Roy S, Patel K, Carbonaro DA et al (2017) Lentivirus mediated correction of Artemis-deficient severe combined immunodeficiency. Hum Gene Ther 28(1):112–124. https://doi.org/10.1089/hum.2016.064 Epub 2016 Sep 7

20.

McCormack MP, Rabbitts TH (2004) Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 350:913–922. https://doi.org/10.1056/NEJMra032207

21.

Hacein-Bey-Abina S, Pai SY, Gaspar HB et al (2014) A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 371(15):1407–1417. https://doi.org/10.1056/NEJMoa1404588 PubMed PMID: 25295500

22.

Verschuren MC, Wolvers-Tettero IL, Breit TM, Noordzij J, van Wering FR, van Dongen JJ (1997) Preferential rearrangements of the T cell receptor-delta-deleting elements in human T cells. J Immunol 158(3):1208–1216CrossRef

23.

Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF et al (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396(6712):690–695. https://doi.org/10.1038/25374

24.

Punwani D, Gonzalez-Espinosa D, Comeau AM, Dutra A, Pak E, Puck JM (2012) Cellular calibrators to quantitate T-cell receptor excision circles (TRECs) in clinical samples. Mol Genet Metab 107(3):586–591. https://doi.org/10.1016/j.ymgme.2012.09.018 Epub 2012 Sep 21

25.

Ravkov E, Slev P, Heikal N (2017) Thymic output: assessment of CD4+ recent thymic emigrants and T-cell receptor excision circles in infants. Cytometry Part B: Clin Cytometry 92(4):249–257. https://doi.org/10.1002/cyto.b.21341 Epub 2016 Jan 28

26.

Hamprecht K, Maschmann J, Vochem M, Dietz K, Speer CP, Jahn G (2001) Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 357(9255):513–518. https://doi.org/10.1016/S0140-6736(00)04043-5

27.

la Marca G, Canessa C, Giocaliere E et al (2013) Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency. J Allergy Clin Immunol 131:1604–1610. https://doi.org/10.1016/j.jaci.2012.08.054 Epub 2012 Dec 30

28.

Fuchs S, Rensing-Ehl A, Erlacher M, Vraetez T, Hartjes L, Janda A et al (2014) Patients with T⁺/low NK⁺IL-2 receptor γ chain deficiency have differentially-impaired cytokine signaling resulting in severe combined immunodeficiency. Eur J Immunol 44:3129–3140. https://doi.org/10.1002/eji.201444689 Epub 2014 Aug 28

29.

Tangye SG, Al-Herz W, Bousfiha A et al (2020) Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee [published correction appears in J Clin Immunol. 2020 Feb 22;]. J Clin Immunol 40(1):24–64. https://doi.org/10.1007/s10875-019-00737-x

30.

Chan A, Scalchunes C, Boyle M, Puck J (2011) Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey. Clin Immunol 138(1):3–8. https://doi.org/10.1016/j.clim.2010.09.010

31.

Sheller R, Ojodu J, Griffin E et al (2020) The landscape of Severe combined immunodeficiency newborn screening in the United States in 2020: A review of screening methodologies and targets, communication pathways, and long-term follow-up practices Front Immunol 11:577853. https://doi.org/10.3389/fimmu.2020.577853

32.

Amatuni GS, Currier RJ, Church JA et al (2019) Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California, 2010–2017. Pediatrics 143(2):e20182300. https://doi.org/10.1542/peds.2018-2300

33.

Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, Chin IK et al (2007) Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. https://doi.org/10.1182/blood-2006-10-048652

34.

Janda A, Sedlacek P, Honig M Freidrich W, Champagne M, Matsumoto T et al (2010) Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly. Blood 116(13):2229–2236. https://doi.org/10.1182/blood-2010-03-275966

35.

Albin-Leeds S, Ochoa J, Mehta H, Vogel BH, Caggana M, Bonagura V et al (2017) Idiopathic T cell lymphopenia identified in New York State newborn screening. Clin Immunol 183:36–40. https://doi.org/10.1016/j.clim.2017.07.002CrossRef

36.

Gans MD, Gavrilova T (2020) Retrospective analysis of a New York newborn screen Severe Combined Immunodeficiency referral center. J Clin Immunol 40(3):456–465. https://doi.org/10.1007/s10875-020-00757-yCrossRef

37.

Jongco AM, Sporter R, Hon E, Elshalgi O, Zhang S, Dalan F et al (2021) Characterization of infants with idiopathic transient and persistent T cell lymphopenia identified by new born screening – a single center experience in New York state. J Clin Immunol 41:610–620. https://doi.org/10.1007/s10875-020-00957-6CrossRef

38.

Newborn blood spot screening for Severe Combined Immunodeficiency by measurement of T-cell receptor excision circles; approved guidelines (2013) 1st ed. CLSI guideline vol 33,4 Wayne, PA: Clinical Laboratory Standards Institute

39.

Amatuni GS, Sciortino S, Currier RJ, Naides SJ, Church JA, Puck JM (2019) Reference intervals for lymphocyte subsets in preterm and term neonates without immune defects. J Allergy Clin Immunol 144(6):1674–1683. https://doi.org/10.1016/j.jaci.2019.05.038 Epub 2019 Jun 18

40.

Remaschi G, Ricci S, Cortimiglia M, De Vitis E, Iannuzzi L, Boni L, Assari C, Dani C (2019) TREC and KREC in very preterm infants: reference values and effects of maternal and neonatal factors. J Matern Fetal Neonatal Med. https://doi.org/10.1080/14767058.2019.1702951

41.

Puck JM (2019) Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Rev 287(1):241–252. https://doi.org/10.1111/imr.12729

42.

Borte S, von Dobeln U, Fasth A, Wang N, Janzi M, Winiarski J, Sack U, Pan-Hammarstrom Q, Borte M, Hammarstrom L (2012) Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood 119(11):2552–2555. https://doi.org/10.1182/blood-2011-08-371021 Epub 2011 Nov 30

43.

Toth B, Volokha A, Mihas A, Pac M, Bernatowska E, Kondratenko I et al (2009) Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study. Molecular Immunol 46(10):2140–2146. https://doi.org/10.1016/j.molimm.2009.03.012 Epub 2009 May 5

44.

Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, Conley ME, Cunningham-Rundles C, Ochs HD (2006) X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine. 85(4):193–202. https://doi.org/10.1097/01.md.0000229482.27398.ad

45.

Bousfiha AA, Jeddane L, El Hafidi N, Benajiba N, Rada N, El Bakkouri J et al (2014) First report on the Moroccan registry of primary immunodeficiencies: 15 years of experience (1998–2012). J Clin Immunol 34(4):459–468. https://doi.org/10.1007/s10875-014-00005-8

46.

Barbaro M, Ohlsson A, Borte S, Jonsson S, Zetterstrom RH, King J et al (2017) Newborn screening for severe primary immunodeficiency diseases in Sweden—a 2-year pilot TREC and KREC screening study. J Clin Immunol 37(1):51–60. https://doi.org/10.1007/s10875-016-0347-5

47.

Mallott J, Kwan A, Church J, Gonzlez-Espinosa D, Lorey F, Tang LF, Sundersan U et al (2013) Newborn screening for SCID identifies patient with Ataxia Telangiectasia. J Clin Immunol 33:540–549. https://doi.org/10.1007/s10875-012-9846

48.

Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS (1998) Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Human Gen 63(4):1049–1059. https://doi.org/10.1086/302054

49.

Hershfield MS (2003) Genotype is an important determinant of phenotype in adenosine deaminase deficiency. Curr Opin Immunol 15(5):571–7. https://doi.org/10.1016/s0952-7915(03)00104-3

50.

la Marca G, Canessa C, Giocaliere E, Romano F, Duse M, Malvagia S, Lippi F et al (2013) Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency. J Allergy Clin Immunol 131(6):1604–1610. https://doi.org/10.1016/j.jaci.2012.08.054 Epub 2012 Dec 30

51.

Al-Dirbashi OY (2015) Tandem mass spectrometric determination of purine metabolites and adenosine deaminase activity for newborn screening of ADA–SCID. LymphoSign 2(3):135–145CrossRef

52.

Collins CJ, Yi F, Dayuha R, Whiteaker JR, Oches HD, Freeman A et al (2020) Multiplexed proteomic analysis for diagnosis and screening of five primary immunodeficiency disorders from dried blood spots. Front Immunol 11:464. https://doi.org/10.3389/fimmu.2020.00464

53.

Kraszewski JN, Kay DM, Stevens CF, Koval C, Haser B, Ortiz V et al (2018) Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med 20(6):608–613. https://doi.org/10.1038/gim.2017.152 Epub 2017 Oct 12

54.

Taylor JL, Lee FK, Yazdanpanah GK, Staropoli J, Liu M, Carulli JP et al (2015) Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. Clin Chem 61(2):412–419. https://doi.org/10.1373/clinchem.2014.231019 Epub 2014 Dec 11

55.

Gutierrez-Mateo C, Timonen A, VaahteraVersheven K, Vaahtera K, Iaakkola M, Hougaard D et al (2019) Development of a multiplex real-time PCR assay for the newborn screening of SCID, SMA, and XLA. Int J Neon Screen 5(4):39. https://doi.org/10.3390/ijns5040039 eCollection 2019 Dec

Title: Newborn Screening in the Diagnosis of Primary Immunodeficiency
Author: Lisa J. Kobrynski
Publication date: 22-07-2021
Publisher: Springer US
Keywords: Primary Immunodeficiency
Lymphopenia
Neonatal Screening
Published in: Clinical Reviews in Allergy & Immunology / Issue 1/2022
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-021-08876-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Agammaglobulinemia: from X-linked to Autosomal Forms of Disease

Future of Therapy for Inborn Errors of Immunity

Spectrum of Genetic T-Cell Disorders from 22q11.2DS to CHARGE

Novel Genetic Discoveries in Primary Immunodeficiency Disorders

Diagnostic Modalities in Primary Immunodeficiency

Defects of the Innate Immune System and Related Immune Deficiencies

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials